Great to hear that the newly formulated MPL tablets for Human Trials have been manufactured.
The MND Trial Patient recruitment will now begin for a truly debilitating disease..
Then the long awaited SARs/Covid Trial can begin ,, with so much compelling data surrounding SARs/ Covid vs MPL I feel this will act as real catalyst driving tremendous interest toward Pharmaust.
Preliminary Positive Results for the Treatment of SARS-CoV-2 Viral Infection by Monepantel
https://stocknessmonster.com/announcements/paa.asx-6A981296/
Confirmation of Preliminary COVID-19 Results Following
Monepantel Treatment In Vitro
https://stocknessmonster.com/announcements/paa.asx-6A982977/
Inhibition of SARS-CoV-2 by Monepantel in Preliminary
Studies of Human Respiratory Calu-3 Cells In Vitro
https://stocknessmonster.com/announcements/paa.asx-6A992675/
Monepantel Anti-viral Activity Against SARS-CoV-2
Confirmed
https://stocknessmonster.com/announcements/paa.asx-6A995129/
PharmAust and Leiden University Evaluate Monepantel
Suitability for Ex-Vivo Human COVID-19 Testing
https://stocknessmonster.com/announcements/paa.asx-6A997384/
Monepantel and monepantel sulfone COVID-19 anti-viral update
• Three individual laboratories have now examined the effects of monepantel (MPS) and
monepantel sulfone (MPLS) upon SARS-COV2 infection, the causal agent of COVID19 disease
• MPL and MPLS significantly protect against COVID-19 virus mediated cell death
• MPL and MPLS appear to inhibit viral infection by targeting late-stage events in the
COVID-19 virus life-cycle
• Evaluation of MPL in COVID-19 patients is being assessed in Europe for when GMP
grade tablets are manufactured
• PharmAust will continue to build its anti-viral preclinical data package by additionally
investigating MPL in HTLV-1 viral infections
26 July 2021 – Perth, Australia: PharmAust Limited (ASXAA), a clinical-stage biotechnology company, is
pleased to provide an update on its anti-viral program investigating the development of monepantel (MPL) and its
metabolite monepantel sulfone (MPLS) as anti-viral therapeutics against SARS-CoV2, the causal agent of
COVID-19 disease.
In collaboration with three independent laboratories, PharmAust has investigated the capacity of MPL and MPLS
in vitro to inhibit:
i) SARS-CoV2-induced cell death,
ii) SARS-CoV2 RNA release from the cell, and
iii) SARS-CoV2 RNA infection of neighbouring cells.
All three laboratories demonstrated that both MPL and MPLS protect against cell death in vitro following infection
with SARS-CoV2. Furthermore, two laboratories investigated the effects of MPL and MPLS upon the early stages
of the SARS-CoV2 virus lifecycle by examining RNA release into the culture media.
With such an amount of compelling Positive data from 3 Independent 3rd Party Research Institutes , as they say the proof is in the Pudding and Covid is about to get a dose of MPL...... Exciting Times ahead..
- Forums
- ASX - By Stock
- Trial Time , MND , SARs / Covid
Great to hear that the newly formulated MPL tablets for Human...
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $82.65M |
Open | High | Low | Value | Volume |
17.0¢ | 18.0¢ | 17.0¢ | $32.57K | 186.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 126411 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 253154 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 125011 | 0.170 |
12 | 223341 | 0.165 |
8 | 332077 | 0.160 |
4 | 512800 | 0.155 |
10 | 378999 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 236237 | 5 |
0.185 | 264496 | 4 |
0.190 | 268528 | 5 |
0.195 | 182632 | 4 |
0.200 | 1144778 | 15 |
Last trade - 11.48am 15/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online